home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Cancer Drugs Research & Development

 
  May 05, 2005  
     
 
GTCbio, Philadelphia, Pennsylvania
May 26-27, 2005


Sessions will include: - The Preclinical Profile of a Novel Cell Cycle (Kinase) Inhibitor
- Small Molecule Inhibitors of Phosphatidylinositol 3-Kinase (PI3-K) Delta for the Treatment of Cancer
- Targeting the p53-MDM2 interaction for Cancer Therapy
- Mechanism of Tumor Cell Death by Histone Deacetylase Inhibitors
- Generation of an Electrofusion Cancer Vaccine: From Concept to Clinical Evaluation
- Myc and Therapeutic Responses in B-lymphoma and Colon Cancer
- S100b as a Predictor of Brain Metastases: Brain vs. Cerebrovascular Damage
- Characterization of a Novel Small Molecule Inhibitor of KSP
- Monoclonal Antibody Targeting of the IGF-I Receptor For the Treatment of Cancer
- Therapeutic and Investigational Uses of the VEGF Trap, A Novel and Potent VEGF Blocking Agent
- Mechanisms of Apoptosis: Opportunities for Drug Screening
- Developing HDAC Inhibitors for Anticancer Therapy: Opportunities and Challenges

Plus a special session will be presented by the National Cancer Institute’s Mouse Models of Human Cancer Consortium (NCI-MMHCC). This session will cover:
- Dissecting Cancer Pathways and their Networks In Vivo
- Impact of an Integrated Preclinical/Clinical Approach on Cancer Mortality
- Conditional Approaches to Target Validation and Credentialing in Vivo
- Using GEMs to Design and Test Interventions
- In Vivo Analysis of Complexities of Targeted Therapies: Response and Resistance to Toxicity
- Using Conditional Approached to Expose new Mechanisms of Prostate Cancer Development

 
 
Organized by: GTCbio
Invited Speakers: KEYNOTE: Joseph D. Purvis, M.D.,
Executive Director Clinical Research,
Section Head Medicines and Sciences
AztraZeneca Pharmaceuticals

Stuart Emanuel, Cancer Therapeutics Research
Johnson & Johnson Pharmaceutical Research & Development

Joel S. Hayflick, Ph.D., Principal Scientist
ICOS Corporation

Zhenping Zhu, M.D., Ph.D., Vice President Antibody Technology
ImClone Systems, Inc.

Ricky Johnstone, Laboratory Head
Peter MacCallum Cancer Centre

Lyubomir Vassilev, Ph.D, Senior Research Leader, Discovery Oncology
Hoffmann-La Roche, Inc.

William Moore, Ph.D., Chief Scientific Officer and Vice President, Research & Development
Locus Pharmaceuticals

NATIONAL CANCER INSTITUTE – MOUSE MODELS OF HUMAN CANCER CONSORTIUM
Michael Lahn, M.D., Medical Advisor
Eli Lilly Research Laboratories

Suxing Liu, Ph.D, Biological Research-Oncology
Schering-Plough Research Institute

William Siders, Ph.D., Senior Scientist, Immunotherapy Research Group
Genzyme Corporation

Andrei Thomas-Tikhonenko, Ph.D., Assistant Professor of Pathology
University of Pennsylvania

Damir Janigro, Ph.D., Professor of Molecular Medicine
Cleveland Clinic Foundation

Axel Hoos, M.D., Ph.D., Senior Director, Clinical Development,
Antigenics Inc.

Pearl S. Huang, Ph.D., Oncology and Proliferative Disease, MMPD, CEDD
GlaxoSmithKline

Dale Ludwig, Ph.D., Senior Director, Department of Cell Engineering & Expression
ImClone Systems, Inc.

Jocelyn Holash, Associate Director of Tumor Angiogenesis,
Regeneron Pharmaceuticals, Inc.

Yigong Shi Ph.D, Professor, Department of Molecular Biology
Princeton University, Thomas Lewis Laboratory

Peter Atadje
Novartis Research Institute

 
Deadline for Abstracts: April 26, 2005
 
Registration: Commercial = $1395
Academic = $595

Register Online: www.gtcbio.com
Or by phone: 626-256-6405

E-mail: christy.bowman@gtcbio.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.